Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mammography screening for women 40-49 years old not supported by data -- NIH panel.

This article was originally published in The Gray Sheet

Executive Summary

MAMMOGRAPHY SCREENING TECHNIQUES TO REDUCE FALSE POSITIVES, INCREASE SENSITIVITY is one of 17 areas that should get further research, a National Institutes of Health consensus panel said at a Jan. 21-23 meeting in Bethesda, Maryland. The panel declined to make a recommendation on the ongoing debate over whether women 40-49 years old should receive regular mammograms, concluding that questions in areas such as false positive rates and potential overtreatment remained unanswered.

You may also be interested in...



Senate HELP Subcommittee Will Assess Value of Screening Mammograms

The American College of Radiology plans to submit testimony to the Senate HELP/Public Health Subcommittee countering recent claims that mammography does not contribute to breast cancer mortality reduction

Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups

Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT007460

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel